Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-2699a in Advanced Solid Tumors
NCT05866692Phase 1Recruiting
- Sponsor
- TYK Medicines
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ty-2699a in solid tumor, triple-negative breast cancer (TNBC), breast cancer and 4 more, sponsored by TYK Medicines. Primary endpoints: Dose Limiting Toxicities at 28 days, Recommended Phase 2 Dose and 2 more. Started Aug 2023; status: recruiting.
02
Drugs
ty-2699a
03
Conditions
solid tumortriple-negative breast cancer (TNBC)breast cancerovarian cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05866692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05866692.